Bibliographie

1- Site de l'Intergroupe Françophone du myèlome

2- Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007 Oct 6;370(9594):1209-18

3- Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H.Lenalidomide: A new therapy for multiple myeloma. Cancer Treat Rev. 2008 Jan 28;

4- Morgan GJ, Davies FE, Cavenagh JD, Jackson GH; on behalf of the United Kingdom Myeloma Forum (UKMF) and the Haematology Oncology Task Force of the British Committee for Standards in Haematology.Position. Statement on the use of bortezomib in multiple myeloma. Int J Lab Hematol. 2008 Feb;30(1):1-10.

5- Sebban C, Biron P, Ghesquieres H. Myelome multiple.

6- San Miguel JF and call. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med 2008; 359: 906-17

7- Haaber J et al. Myeloma call expression of 10 candodats genes for osteolytic bone diseases. Only overexpression of DkkMyeloma. Br J haematol 2008; 140: 25-35